Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
US Market
Holding RXRX?
Track your performance easily

Recursion Pharmaceuticals (RXRX) Ownership - Who Owns Recursion Pharmaceuticals?

1,775 Followers

Recursion Pharmaceuticals (RXRX) Ownership Overview

4.98%13.19%4.90%27.10%49.83%
4.90% Other Institutional Investors
27.10% ETFs
49.83% Public Companies and Individual Investors
The ownership structure of Recursion Pharmaceuticals (RXRX) stock is a mix of institutional, retail, and individual investors. Approximately 45.19% of the company’s stock is owned by Institutional Investors, 4.98% is owned by Insiders, and 49.83% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Mar 08, 2024
Christopher Gibson
Ceo,director
xxxxxxxxxxxxx
$396200
Feb 09, 2024
Christopher Gibson
Ceo,director
xxxxxxxxxxxxx
$91300
Jan 05, 2024
Christopher Gibson
Ceo,director
xxxxxxxxxxxxx
$339150
Dec 08, 2023
Christopher Gibson
Ceo,director
xxxxxxxxxxxxx
$74200

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
30,959,248Institution10.89%200,615,927
28,142,918Institution9.90%182,366,109
23,333,950Institution8.21%151,203,996
18,689,902Institution6.58%121,110,565
15,384,615Institution5.41%99,692,305
11,161,806Institution3.93%72,328,503
7,713,452Institution2.71%49,983,169
7,089,007Insider2.49%45,936,765
4,121,651Institution1.45%26,708,298
3,188,547Insider1.12%20,661,785

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
18,689,902Institution6.58%121,110,565
4,121,651Institution1.45%26,708,298
2,507,332Institution0.88%16,247,511
2,448,527Institution0.86%15,866,455
2,334,809Institution0.82%15,129,562
1,676,552Institution0.59%10,864,057
954,110Institution0.34%6,182,633
744,878Institution0.26%4,826,809
628,100Institution0.22%4,070,088
598,537Institution0.21%3,878,520

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
17,871,896Institution6.29%115,809,886
13,068,328Institution4.60%84,682,765
8,012,723Institution2.82%52,803,845
7,192,985Institution2.53%45,747,385
6,205,856Institution2.18%40,896,591
6,161,761Institution2.17%39,928,211
3,529,975Institution1.24%23,262,535
3,417,672Institution1.20%22,522,458
2,114,847Institution0.74%13,704,209
1,523,785Institution0.54%9,874,127

FAQ

Who Owns Recursion Pharmaceuticals (RXRX)?
According to the latest TipRanks data, approximately 4.90% of the company's stock is held by institutional investors, 4.98% is held by insiders, and 49.83% is held by retail investors.
    What percentage of Recursion Pharmaceuticals (RXRX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 4.90% of Recursion Pharmaceuticals (RXRX) stock is held by institutional investors.
      What percentage of Recursion Pharmaceuticals (RXRX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 49.83% of Recursion Pharmaceuticals (RXRX) stock is held by retail investors.
        Who owns the most shares of Recursion Pharmaceuticals (RXRX)?
        ARK owns the most shares of Recursion Pharmaceuticals (RXRX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis